Quick Dispatch:
Your glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies ships.
Need Help?
Questions about glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies in your area.
Frontiers
29.05
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy
21.16
Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications
21.62
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
25.14
Nature: Dual-active molecules targeting GLP-1R and NMDA receptors exhibit superior anti-obesity effects
22.06
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
24.69
The GLP-1 Agonists and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy
22.49
